High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic Risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: Updated analyses from Eastern Cooperative Oncology trial E1900 Meeting Abstract


Authors: Luskin, M. R.; Lee, J. W.; Fernandez, H. F.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Paietta, E. M.; Litzow, M.; Abdel-Wahab, O.; Patel, J. P.; Levine, R. L.; Sun, Z. X.; Luger, S. M.
Abstract Title: High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic Risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: Updated analyses from Eastern Cooperative Oncology trial E1900
Meeting Title: 56th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 124
Issue: 21
Meeting Dates: 2014 Dec 6-9
Meeting Location: San Francisco, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2014-12-06
Language: English
ACCESSION: WOS:000349243505099
PROVIDER: wos
Notes: Meeting Abstract: 373 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos